199 related articles for article (PubMed ID: 37383238)
21. Potential role of Bacillus Calmette-Guérin (BCG) vaccination in COVID-19 pandemic mortality: Epidemiological and Immunological aspects.
Charoenlap S; Piromsopa K; Charoenlap C
Asian Pac J Allergy Immunol; 2020 Sep; 38(3):150-161. PubMed ID: 32686943
[TBL] [Abstract][Full Text] [Related]
22. Modelling the effect of discontinuing universal Bacillus Calmette-Guérin vaccination in an intermediate tuberculosis burden setting.
Fu H; Lin HH; Hallett TB; Arinaminpathy N
Vaccine; 2018 Sep; 36(39):5902-5909. PubMed ID: 30143270
[TBL] [Abstract][Full Text] [Related]
23. Tuberculosis vaccines: beyond bacille Calmette-Guerin.
McShane H
Philos Trans R Soc Lond B Biol Sci; 2011 Oct; 366(1579):2782-9. PubMed ID: 21893541
[TBL] [Abstract][Full Text] [Related]
24. Bacille Calmette-Guérin Vaccination in Infancy Does Not Protect Against Coronavirus Disease 2019 (COVID-19): Evidence From a Natural Experiment in Sweden.
de Chaisemartin C; de Chaisemartin L
Clin Infect Dis; 2021 May; 72(10):e501-e505. PubMed ID: 32829400
[TBL] [Abstract][Full Text] [Related]
25. Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial.
Nemes E; Hesseling AC; Tameris M; Mauff K; Downing K; Mulenga H; Rose P; van der Zalm M; Mbaba S; Van As D; Hanekom WA; Walzl G; Scriba TJ; McShane H; Hatherill M;
Clin Infect Dis; 2018 Feb; 66(4):554-563. PubMed ID: 29028973
[TBL] [Abstract][Full Text] [Related]
26. Is the decline in neonatal mortality in northern Ghana, 1996-2012, associated with the decline in the age of BCG vaccination? An ecological study.
Welaga P; Debpuur C; Aaby P; Hodgson A; Azongo DK; Benn CS; Oduro AR
BMJ Open; 2018 Dec; 8(12):e023752. PubMed ID: 30552267
[TBL] [Abstract][Full Text] [Related]
27. BCG vaccination in India and tuberculosis in children: newer facets.
Udani PM
Indian J Pediatr; 1994; 61(5):451-62. PubMed ID: 7744445
[TBL] [Abstract][Full Text] [Related]
28. Observational study to estimate the changes in the effectiveness of bacillus Calmette-Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK.
Mangtani P; Nguipdop-Djomo P; Keogh RH; Trinder L; Smith PG; Fine PE; Sterne J; Abubakar I; Vynnycky E; Watson J; Elliman D; Lipman M; Rodrigues LC
Health Technol Assess; 2017 Jul; 21(39):1-54. PubMed ID: 28738015
[TBL] [Abstract][Full Text] [Related]
29. Nonspecific (Heterologous) Protection of Neonatal BCG Vaccination Against Hospitalization Due to Respiratory Infection and Sepsis.
de Castro MJ; Pardo-Seco J; Martinón-Torres F
Clin Infect Dis; 2015 Jun; 60(11):1611-9. PubMed ID: 25725054
[TBL] [Abstract][Full Text] [Related]
30. The influence of vaccination against tuberculosis with the Bacillus-Calmette-Guérin(BCG) vaccine on COVID-19 incidence and mortality - review of the literature.
Ręka G; Korzeniowska A; Piecewicz-Szczęsna H
Przegl Epidemiol; 2020; 74(2):290-302. PubMed ID: 33115218
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of Bacillus Calmette-Guérin (BCG) Vaccination in Reducing the Incidence and Severity of COVID-19 in High-Risk Population (BRIC): a Phase III, Multi-centre, Quadruple-Blind Randomised Control Trial.
Sinha S; Ajayababu A; Thukral H; Gupta S; Guha SK; Basu A; Gupta G; Thakur P; Lingaiah R; Das BK; Singh UB; Singh R; Narang R; Bhowmik D; Wig N; Modak DC; Bandyopadhyay B; Chakrabarty B; Kapoor A; Tewari S; Prasad N; Hashim Z; Nath A; Kumari N; Goswami R; Pandey S; Pandey RM
Infect Dis Ther; 2022 Dec; 11(6):2205-2217. PubMed ID: 36242739
[TBL] [Abstract][Full Text] [Related]
32. Newborn bacille Calmette-Guérin vaccination induces robust infant interferon-γ-expressing natural killer cell responses to mycobacteria.
Murphy M; Suliman S; Briel L; Veldtsman H; Khomba N; Africa H; Steyn M; Snyders CI; van Rensburg IC; Walzl G; Chegou NN; Hatherill M; Hanekom WA; Scriba TJ; Nemes E
Int J Infect Dis; 2023 May; 130 Suppl 1():S52-S62. PubMed ID: 36842756
[TBL] [Abstract][Full Text] [Related]
33. The impact of BCG dose and revaccination on trained immunity.
Debisarun PA; Kilic G; de Bree LCJ; Pennings LJ; van Ingen J; Benn CS; Aaby P; Dijkstra H; Lemmers H; Domínguez-Andrés J; van Crevel R; Netea MG
Clin Immunol; 2023 Jan; 246():109208. PubMed ID: 36565972
[TBL] [Abstract][Full Text] [Related]
34. Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?
Moliva JI; Turner J; Torrelles JB
Vaccine; 2015 Sep; 33(39):5035-41. PubMed ID: 26319069
[TBL] [Abstract][Full Text] [Related]
35. The Long-term Effect of Bacille Calmette-Guérin Vaccination on Tuberculin Skin Testing: A 55-Year Follow-Up Study.
Mancuso JD; Mody RM; Olsen CH; Harrison LH; Santosham M; Aronson NE
Chest; 2017 Aug; 152(2):282-294. PubMed ID: 28087302
[TBL] [Abstract][Full Text] [Related]
36. Interacting, Nonspecific, Immunological Effects of Bacille Calmette-Guérin and Tetanus-diphtheria-pertussis Inactivated Polio Vaccinations: An Explorative, Randomized Trial.
Blok BA; de Bree LCJ; Diavatopoulos DA; Langereis JD; Joosten LAB; Aaby P; van Crevel R; Benn CS; Netea MG
Clin Infect Dis; 2020 Jan; 70(3):455-463. PubMed ID: 30919883
[TBL] [Abstract][Full Text] [Related]
37. Prevention of infant eczema by neonatal Bacillus Calmette-Guérin vaccination: The MIS BAIR randomized controlled trial.
Pittet LF; Messina NL; Gardiner K; Freyne B; Abruzzo V; Francis KL; Morrison C; Zufferey C; Vuillermin P; Allen KJ; Ponsonby AL; Robins-Browne R; Shann F; Flanagan KL; Phillips R; Donath S; Casalaz D; Curtis N
Allergy; 2022 Mar; 77(3):956-965. PubMed ID: 34309859
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis B vaccine co-administration influences the heterologous effects of neonatal BCG vaccination in a sex-differential manner.
Pittet LF; Cox L; Freyne B; Germano S; Bonnici R; Gardiner K; Donath S; Collins CL; Casalaz D; Robins-Browne R; Flanagan KL; Messina NL; Curtis N
Vaccine; 2022 Feb; 40(9):1334-1341. PubMed ID: 35105495
[TBL] [Abstract][Full Text] [Related]
39. Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark.
Madsen AMR; Schaltz-Buchholzer F; Benfield T; Bjerregaard-Andersen M; Dalgaard LS; Dam C; Ditlev SB; Faizi G; Johansen IS; Kofoed PE; Kristensen GS; Loekkegaard ECL; Mogensen CB; Mohamed L; Ostenfeld A; Oedegaard ES; Soerensen MK; Wejse C; Jensen AKG; Nielsen S; Krause TG; Netea MG; Aaby P; Benn CS
Trials; 2020 Sep; 21(1):799. PubMed ID: 32943115
[TBL] [Abstract][Full Text] [Related]
40. Bacillus Calmette-Guérin (BCG) vaccine adverse events in Victoria, Australia: analysis of reports to an enhanced passive surveillance system.
Clothier HJ; Hosking L; Crawford NW; Russell M; Easton ML; Quinn JA; Buttery JP
Drug Saf; 2015 Jan; 38(1):79-86. PubMed ID: 25475539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
